Month: December 2015


Kain Lawyers helps Cytomatrix secure significant IP licensing deal

Kain Lawyers has helped Melbourne stem cell therapeutics company, Cytomatrix Limited, on its development of a $100m US-based business to progress cancer treatments using umbilical cord blood stem cells. It was one of this year’s biggest research and IP licensing deals in Australia. Corporate law specialists Gerry Cawson and James Burchnall developed a transaction structure… Read more


A day in the life of a Kain Lawyers summer clerk

In the second of our video series, our three summer clerks Ben, Sara and Georgina share a day in the life of a summer clerk at Kain Lawyers. At Kain Lawyers we select candidates who have the skills and cultural alignment to become long-term members of our team and help us achieve our strategic objectives. It’s… Read more


Kain Lawyers Summer Clerks give their first impressions of the business

In the first of our video series, our three summer clerks Ben, Sara and Georgina give their impressions of Kain Lawyers and talk about their expectations and outcomes from joining the program. At Kain Lawyers we select candidates who have the skills and cultural alignment to become long-term members of our team and help us achieve our… Read more


Can ASX-listed biotech companies balance their continuous disclosure obligations with international scientific best practice in reporting?

ASX-listed biotech companies are required to disclose material information without delay in order to comply with the ASX’s continuous disclosure rules. They also operate in an industry where reputations can be destroyed through the premature release of scientific information that has not been appropriately stress-tested. In this article we consider whether it is possible to… Read more